Table 1.

ACC/AHA Clinical Guideline Recommendations for Treatment of Stage B HF

Recommendations	Class of Recommendation	Level of Evidence
In patients with a history of MI and low EF, ACE inhibitors or ARBs should be used to prevent HF	I	A
In patients with MI and low EF, evidence-based beta blockers should be used to prevent HF	I	B
In patients with MI, statins should be used to prevent HF	I	A
Blood pressure should be controlled to prevent symptomatic HF	I	A
ACE inhibitors should be used in all patients with a reduced EF to prevent HF	I	A
Beta blockers should be used in all patients with a reduced EF to prevent HF	I	C
An ICD is reasonable in patients with asymptomatic ischemic cardiomyopathy who are at least 40 d post-MI, have an LVEF ≤30%, and on GDMT	IIa	B
Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF	III: Harm	C

Abbreviations: ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; and MI, myocardial infarction.

Data from Yancy CW, Jessup M, Bozkurt B, et al: 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; Published online on June 3 at doi:pii: S0735-1097(13)02114-1. 10.1016/j.jacc.2013.05.019., with permission from Elsevier.